Jazz Pharmaceuticals Announces Acquisition of Actio Biosciences (up to $1.32B)

What Happened
Jazz Pharmaceuticals plc (via its subsidiary Jazz Pharmaceuticals, Inc.) entered into an Agreement and Plan of Merger on August 10, 2026 to acquire Actio Biosciences, Inc. The deal provides for an initial Aggregate Upfront Transaction Value based on $820,000,000 (subject to customary adjustments) that will be converted into an Upfront Per Share Amount at closing. The agreement also includes up to $500,000,000 of contingent milestone payments tied to regulatory approval and sales of ABS-1230.

Key Details

• Merger agreement signed Aug 10, 2026: Parent (Jazz Pharmaceuticals, Inc.) will merge its Merger Sub (Knight Acquisition Corp.) into Actio; Actio will survive as a wholly owned subsidiary.
• Upfront consideration: initial $820,000,000 (adjusted for cash, unpaid transaction expenses, indebtedness, taxes, other liabilities); per-share payout = Aggregate Upfront Transaction Value ÷ fully diluted shares.
• Contingent milestones (total up to $500M): $250M on regulatory approval of ABS-1230 for KCNT1-Related Epilepsy; $100M at $500M annual net sales; $150M at $1B annual net sales.
• Equity instruments: outstanding in-the-money Actio options will be net-settled (holders receive Upfront Per Share Amount less exercise price); underwater options/warrants terminated for no consideration; Actio will seek holders’ consent to cancel outstanding warrants for consideration in the merger.
• Closing conditions and mechanics: deal requires customary conditions (accurate reps/warranties, no material adverse effect, HSR clearance/other approvals), adoption by Actio stockholders (including holders of at least 85% of outstanding shares), completion of a required Spin-Out transferring non-ABS-1230 programs to a new SpinCo (Jazz to hold a minority stake), and there is an “End Date” of five months after the agreement date. No termination fee is provided.

Why It Matters
This agreement adds Actio’s ABS-1230 program to Jazz’s clinical portfolio, with potential near-term regulatory and commercial milestones that could bring significant contingent payments. The transaction’s upfront value and substantial milestone upside define the maximum consideration (~$1.32B if all milestones are achieved), but closing is subject to multiple conditions (including regulatory clearances, a required spin-out and a supermajority stockholder vote), so it is not guaranteed to close. Investors should note the contingent nature of up to $500M in future payments, the treatment of Actio equity awards and warrants, and that Jazz disclosed customary forward-looking risks in the filing.